Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Monoclonal antibody or fragment thereof
Reexamination Certificate
2006-07-04
2006-07-04
Gambel, Phillip (Department: 1644)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Monoclonal antibody or fragment thereof
C424S130100, C424S134100, C424S141100, C424S143100, C424S144100, C424S153100, C424S173100, C530S387100, C530S388200, C530S388220, C530S388700, C530S388730, C530S388750, C530S389100, C530S389600
Reexamination Certificate
active
07070777
ABSTRACT:
This invention provides for methods of inhibiting inflammation with antibodies that bind the 5c8 protein.
REFERENCES:
patent: 5102909 (1992-04-01), Veltri et al.
patent: 5340829 (1994-08-01), Clark et al.
patent: 5474771 (1995-12-01), Lederman et al.
patent: 5683693 (1997-11-01), Noelle et al.
patent: 5747037 (1998-05-01), Noelle et al.
patent: 5833987 (1998-11-01), Noelle et al.
patent: 5961974 (1999-10-01), Armitage et al.
patent: 5993816 (1999-11-01), Lederman et al.
patent: 0555880 (1993-08-01), None
patent: 9007861 (1990-07-01), None
patent: 9308207 (1993-04-01), None
patent: WO9506480 (1995-03-01), None
patent: WO9623071 (1996-08-01), None
patent: WO9830240 (1998-07-01), None
patent: WO9830241 (1998-07-01), None
Paul (H2 ) Fundamental Immunology 3rd(8). Raven Press p. 242 only 1993.
Noelle Immunity 4 : 415-419 (1996).
Edgington Biotechnology 11: 998-1000 (1993).
Durie et al., J. Clin. Invest. 94: 1333-1338 (1994).
Lenz et al., J. Clin Invest. 92: 2587-2596 (1993).
Lederman et al. Research in Immunology 145(3) 215-221(1994).
Akdis et al. (1997)Eur. J. Immunol. 27:2351-2357.
Bartlett, W.C., et al. (1990).J. Immunol. 145: 3956-3962.
Callard et al. (1993)Imm. Today14:559-564.
Christadoss, P. and Dauphinee, M.J. (1986)J. Immunol. 136:2437-2440.
Clark, E.A. and Ledbetter, J.A. (1986)Proc. Natl. Acad. Sci. USA83:4494-4498.
Cosimi A.B. et al (1981)Transplant Proc13:499-503.
Durie et al. (1994)J. Clin. Invest. 94:1333-38.
Edgington et al. (1993)Biotech. 11:998-1000.
Freeman, G. J., et al.(1991).J. Exp. Med.174:625-631.
Gascan H. et al. (1991)J. Immunol147:8-13.
Goldberg D. et al. (1991)J. Autoimmun. 4:617-630.
Gordon J. et al. (1988)J. Immunol. 140:1425-1430.
Hafler D.A. (1988)J. Immunol141:131-138.
Reiter C. et al. (1991)Arthiritis&Rheum. 34:525-36.
Satoh J. et al. (1988)J. Neuroimmunol.18:105-116.
Schwarz R.H. et al. (1990)Sci. 248:1349-1356.
Shizuru J.A. et al. (1988)Sci. 240659-662.
Snow E. C . et al. (1989)Fed. Am. Soc. for Exp. Bio. 73rdmeeting Abs No.4267.
Sriram S. et al. (1986)J. Immunol. 136:4464-69.
Stull S.J. at al. (1988)Cell Immunol. 117:188-98.
Traugott U. (1983)Science219:308-310.
Traugott U. (1983)J. Neuroimmunol. 4:201-21.
Valent P. et al. (1990)Int. Arch. Allergy. Appl. Immunol. 91:198-203.
van Seventer G.A. et al. (1990)J. Immunol. 144:4579-4586.
Waldmann H. et al. (1989)Ann. Rev. Immunol. 7:407-444.
Waldor M.K. et al (1985)Sci. 227:415-17.
Williams I.R. et al. (1990)J. Immunol. 145:85-93.
Wofsy, D., et al. (1985).J. Immunol. 134:852-857.
Wofsy, D. and Seaman, W.E. (1985). (S.H. Pincus, et al. eds.), pp. 187-195.
Wofsy, D. and Seaman, W.E. (1985).J. Exp.Med. 161:378-391.
Wofsy, D. and Seaman, W.E. (1987).J. Immunol. 138:3247-3253.
Wofsy, D. (1986).J. Immunol. 136:4554-4560.
Wofsy, D. and Carteron, N.L. (1990).Semin. Immunol. 2:419-425.
Young, L.S., et al. (1989)Int. J. Cancer43:786-794.
Haynes M. K. et al. (1987)Diabetes36:877-881.
Horneff G. et al. (1991)Arthritis&Rheum. 34:129-140.
Jenkins M.K. et al. (1987)J. Exp. Med. 165:302-319.
Junghans R.P. (1990)Cancer Res. 50:1495-1502.
Kennedy M.K .(1987)J. Neuroimmunol. 16:345-364.
Koike T. (1987)Diabetes36:539-541.
Kung P.C. et al. (1979)Sci. 206:347-349.
Kung P.C. et al. (1980)Vox. Sang. 39:121-127.
Lederman S. et al. (1994)Res. in Imm. 145(3):215-221.
Lenz et al. (1993)J. Clin. Invest. 92:2587-2596.
Ling N.R. (1987) A.J. Michaels ed p302-35.
Linsley P.S. et al. (1991)J. Exp. Med. 174:561-569.
Madec A.M. et al. (1996)J. Immunol. 156:3541-3549.
Marshall L. S. et al. (1990)Res. Immunol. 141:412-417.
Noelle R.J. et al (1996)Immunity4:415-19.
Noelle R. (1990)Imm.Today11(10):361-68.
Paul (Ed)Fund. Imm., Third Edition Raven Press p242 (1993).
Pisetsky D.S. (1985) in Pincus S.H. et al eds. p171-76.
Potocnik A.J. et al. (1990)Scand. J. Immol. 31:213-224.
Ranges G.E et al. (1985)J. Exp. Med. 162:1105-1110.
Reinherz E.L. et al. (1979)J. Exp. Med. 150:1472-1482.
R.J. Armitage, et al.,Nature(1992) 357:80-82.
P. Lane, et al.,Eur. J. Immunol. (1992) 22:2573-2578.
L.S. Marshall and R.J. Noelle,FASEB J. (1991) 5(4):A608; Abstract No. 1379.
R.J. Noelle, et al.,Proc. Natl. Acad. Sci USA(1992) 89:6550-6554.
R.J. Noelle, et al.,Immunol. Today(1992) 13(11):431-433.
R.J. Noelle and E.C. Snow,FASEB J. (1991) 5(13):2770-2776.
R. Noelle and E.C. Snow,Current Opinion in Immunology(1992) 333-337.
R.J. Noelle, et al. inMechanisms of Lymphocyte Activation and Immune Regulation IV: Cellular Communications, S. Gupta and T.A. Waldmann, eds. (Plenum, New York 1992) 131-137.
Waldmann, T.A.,Science(1991) 252:1657-1662.
Cunningham, C., et al.,TIBTECH(1992) vol. 10.
Rogozinski, et al.,J. Immunol. (1984) 132:735-739.
Dillman, R.O.,Annals Int. Med. (1989) 111:592-603.
Weiss, et al.,Adv. Immunol. (1987) 41:1-38.
Harris, W., et al.,TIBTECH(1993) 11:42-44.
Lederman, et al.,J. Exp. Med. (1992) 175:1091-1101.
Joliffe, L.K.,Intern. Rev. Immunol. (1993) 10:241-250.
Borrebaeck, C.A.K., et al.,Immunol. Today(1993) 14:477-482.
Kahan, B.,Current Opin. Immunol. (1992) 4:553-560.
Tueveson, G., et al.,Immunol. Rev. (1993) Issue No. 136:99-109.
Emery, S.C., et al.,Exp. Opin. Invest. Drugs(1994) 3:241-251.
Winter, G., et al.,TIPS(1993) 14:139-143.
Borst, J., et al.,Eur. J. Immunol. (1989) 19:357-364.
Brian, A.,Proc. Natl. Acad. Sci. USA(1988) 85:564-568.
Crow, M.K., et al.,Cell. Immunol. (1989) 121:99-112.
Damle, N.K., et al.,Eur. J. Immunol. (1991) 21:1277-1282.
Hirohata, S., et al.J. Immunol. (1988) 140(11):3736-3744.
Hodgkin, P.D., et al.,J. Immunol. (1990) 145:2025-2034.
Kubota, E., et al.,Immunol. (1991) 72:40-47.
Noelle, R.J., et al.,J. Immunol. (1989) 143(6):1807-1814.
Noelle, R.J., et al.,J. Immunol. (1991) 146(4):1118-1124.
Rabin, E.M., et al.,Proc. Natl. Acad. Sci. USA(1985) 82:2935-2939.
Reinherz, E.L., et al.,J. Exp. Med. (1979) 150:1472-1482.
Sanders, V.M., et al.,J. Immunol. (1986) 137(8):2395-2404.
Sekita, K., et al.,Eur. J. Immunol. (1988) 18:1405-1410.
Smith, S.H., et al.,Immunol. (1986) 58:63-70.
Tohma, S., Hirohata, S., and Lipsky, P.E.,J. Immunol. (1991) 146(2):492-499.
Tohma, S., and Lipsky, P.E.,J. Immunol. (1991) 146(8):2544-2552.
Torimoto, Y., et al.,J. Immunol. (1991) 146(7):2176-2184; and.
Lauzon, G.J., et al.,Molecular Immunology(1988) 25(9):829-841.
G. Inghirami, et al.,Blood(1994) 84:866-872.
J. Hakimi, et al.,J. Immunol. (1991) 147:1352-1359.
C. Queen, et al.,Proc. Natl. Acad. Sci. USA(1989) 86:10029-10033.
Press Release from Biogen, Inc., dated Oct. 21, 1999, “Biogen Says It Has Halted Several Trials of Anti-CD40 Ligand Monoclonal Antibody” (Exhibit B).
Press Release from Biogen, Inc., dated Nov. 2, 1999, “Biogen Says It Has Stopped Ongoing Trials of Anti-CD40 Ligand Monoclonal Antibody” (Exhibit C).
Press Release from IDEC Pharmaceuticals, Inc., dated Apr. 20, 2000, “First Quarter 2000 Results” (see section entitled “IDEC-131 (anti-CD40L)”) (Exhibit D).
BioWorld Today, Oct. 25, 1999, “Biogen Halts Trials of Antova After Reporting Adverse Events” (Exhibit E).
Gray, D. et al. (1994) J. Exp. Med. 180:141-155 (Exhibit F).
Stüber, E. et al. (1996) J. Exp. Med. 183:693-698 (Exhibit G).
Jaffar, Z. H. et al. (1999) J. of Immunology, 6283-6291 (Exhibit H).
Akdis, C. A. et al. (1997) Eur. J. Immunology 27:2351-2357 (Exhibit I).
Buhlmann J Clin Immunol. 16:83-89 (1996).
Resetkova et al. Thyroid 6: 267-273 (1996).
Stuber et al. J. Exp. Med. 183: 693-698 (1996).
Gray et al. J. Exp Med. 180: 141-155 (1994).
Biacone et al. Kidney Intl. 48: 458-468 (1995).
Larsen Transplantation 61: 4-9 (1996).
Datta Arthritis and Rheumatism.
Strom T.B. et al. 1989, “Toward More Selective Therapies to Block Undesired Immune Responses”,Kidney International35(4):1026-1033. (Exhibit 1).
Yellin M.J. et al. 1991, “A Human CD4 Negative T-Cell Leukemia Cell Subclone with Contact-Dependent Helper Function”,Journal of Immunology147(10): 3389-3395. (Exhibit 2).
Lederman S. et al. 1992, “Anti-CD40 Monoclonal Antibody Blocks the Contact Dependent T Helper Signal Medicated by 5c8 Antigen”,Clinical Research40(2) :154A. (Exhibit 3).
Chess Leonard
Lederman Seth
Yellin Michael J.
Cooper & Dunham LLP
Gambel Phillip
The Trustees of Columbia University in the City of New York
White John P.
LandOfFree
Method for inhibiting inflammation with an antibody that... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method for inhibiting inflammation with an antibody that..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method for inhibiting inflammation with an antibody that... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3524393